Tumor Biology

, Volume 37, Issue 8, pp 11289–11297 | Cite as

MicroRNA-183 promotes migration and invasion of CD133+/CD326+ lung adenocarcinoma initiating cells via PTPN4 inhibition

  • Conghui Zhu
  • Xi Deng
  • Jingbo Wu
  • Jianwen Zhang
  • Hongru Yang
  • Shaozhi Fu
  • Yan Zhang
  • Yunwei Han
  • Yuanmei Zou
  • Zhengtang ChenEmail author
  • Sheng LinEmail author
Original Article


Non-small cell lung cancer (NSCLC) is the most common cancer worldwide and is a leading cause of lung cancer mortality due to early stage metastases. Cancer stem-like cells (CSLCs) or tumor-initiating cells (TICs) are rare subpopulation cells that are responsible for maintaining tumor growth and invasion leading to recurrence and metastasis. Previous studies revealed that miR-183 can mediate the invasiveness and growth of NSCLC. However, the exact role of miR-183 in regulating the biological behavior of CSLCs in NSCLC remains unclear. In the present study, we explored the regulation of protein tyrosine phosphatase non-receptor type 4 (PTPN4) by miR-183 in vitro using luciferase reporter assays, and we further analyzed the effects of miR-183 on the invasiveness of CSLCs in vitro and in vivo using transwell and bioluminescence assays. Following our finding that miR-183 binds to PTPN4 messenger RNA (mRNA) to prevent its translation through the 3′-untranslated region (UTR), we found that overexpression of miR-183 in CSLCs decreased PTPN4 protein levels while inhibition of miR-183 increased PTPN4 protein levels. The suppression of PTPN4 levels in CSLCs by miR-183 paralleled with a significant promotion in their motility in vitro and in vivo, while anti-sense miR-183 increased PTPN4 levels in CSLCs, which paralleled with a significant decrease in their invasiveness. Furthermore, correlation analysis between miR-183 and PTPN4 in clinical samples demonstrated a statistically significant inverse correlation between PTPN4 mRNA levels and miR-183. In brief, our data indicate that miR-183 plays a pro-invasive role by inverse regulation of PTPN4, and this axis may be a new therapeutic target for suppressing the metastatic capability of CSLCs in NSCLC.


miR-183 PTPN4 CD133/CD326 Cancer stem-like cells Tumor-initiating cells 



This work was supported by the National Natural Science Foundation of China (NSFC81201682).

Compliance with ethical standards

The care and use of mice was performed in accordance with ethical guidelines of Southwest Medical University.


  1. 1.
    Long HX, Xiang T, Qi W, Huang J, Chen J, He L, et al. CD133+ ovarian cancer stem-like cells promote non-stem cancer cell metastasis via CCL5 induced epithelial-mesenchymal transition. Oncotarget. 2015;6(8):5846–59.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Roberto GC, Chitralekha B, Nandita G, Lisa B, Per B, Michael G, et al. Non-small cell lung cancer cells survived ionizing radiation treatment display cancer stem cell and epithelial-mesenchymal transition phenotypes. Mol Cancer. 2013;12(2):390–7.Google Scholar
  3. 3.
    Yang L, Ping YF, Yu X, Qian F, Guo ZJ, Qian C, et al. Gastric cancer stem-like cells possess higher capability of invasion and metastasis in association with a mesenchymal transition phenotype. Cancer Lett. 2011;310(1):46–52.PubMedGoogle Scholar
  4. 4.
    Hiraga T, Ito S, Nakamura H. Cancer stem-like cell marker CD44 promotes bone metastases by enhancing tumorigenicity, cell motility, and hyaluronan production. Cancer Res. 2013;73(13):4112–22.CrossRefPubMedGoogle Scholar
  5. 5.
    Vira D, Basak SK, Veena MS, Wang MB, Batra RK, Srivatsan ES. Cancer stem cells, microRNAs, and therapeutic strategies including natural products. Cancer Metastasis Rev. 2012;31(3-4):733–51.CrossRefPubMedGoogle Scholar
  6. 6.
    Ji J, Yamashita T, Budhu A, Forgues M, Jia HL, Li C, et al. Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells. Hepatology. 2009;50(2):472–80.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Ma C, Huang T, Ding YC, Yu W, Wang Q, Meng B, et al. microRNA-200c overexpression inhibits chemoresistance, invasion and colony formation of human pancreatic cancer stem cells. Int J Clin Exp Pathol. 2015;8(6):6533–9.PubMedPubMedCentralGoogle Scholar
  8. 8.
    Daisuke Y, Toru K, Shiro O, Hisaaki T, Madoka I, Ryo M, et al. Mir340 suppresses the stem-like cell function of glioma-initiating cells by targeting tissue plasminogen activator. Cancer Res. 2015;75(6):1123–33.CrossRefGoogle Scholar
  9. 9.
    Nandy SB, Arumugam A, Subramani R, Pedroza D, Hernandez K, Saltzstein E, et al. Microrna-125a influences breast cancer stem cells by targeting leukemia inhibitory factor receptor which regulates the hippo signaling pathway. Oncotarget. 2015;6(19):17366–78.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Liu T, Qin W, Hou L, Huang Y. Microrna-17 promotes normal ovarian cancer cells to cancer stem cells development via suppression of the LKB1-p53-p21/WAF1 pathway. Tumour Biol. 2014;36(3):1881–93.CrossRefPubMedGoogle Scholar
  11. 11.
    Hwang WL, Jiang JK, Yang SH, Huang TS, Lan HY, Teng HW, et al. MicroRNA-146a directs the symmetric division of snail-dominant colorectal cancer stem cells. Nat Cell Biol. 2014;16(3):268–80.CrossRefPubMedGoogle Scholar
  12. 12.
    Hsieh IS, Chang KC, Tsai YT, Ke JY, Lu PJ, Lee KH, et al. Microrna-320 suppresses the stem cell-like characteristics of prostate cancer cells by downregulating the Wnt/beta-catenin signaling pathway. Carcinogenesis. 2013;34(3):530–8.CrossRefPubMedGoogle Scholar
  13. 13.
    Lin S, Sun JG, Wu JB, Long HX, Zhu CH, Xiang T, et al. Aberrant microRNAs expression in CD133+/CD326+ human lung adenocarcinoma initiating cells from A549. Mol Cells. 2012;33(3):277–83.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Huai W, Song H, Wang L, Li B, Zhao J, Han L, et al. Phosphatase PTPN4 preferentially inhibits TRIF-dependent TLR4 pathway by dephosphorylating tram. J Immunol. 2015;194(9):4458–65.CrossRefPubMedGoogle Scholar
  15. 15.
    Zhou J, Wang BB, Shan JX, Shi HL, Li YH, Huo KK. PTPN4 negatively regulates CRKI in human cell lines. Cell Mol Biol Lett. 2013;18(2):297–314.CrossRefPubMedGoogle Scholar
  16. 16.
    Douglas RH, Mick DE, Gray KS, Christopher C, Benz KSV, Danny RW. Breast cancer metastasis suppressor1 up-regulates miR-146, which suppresses breast cancer metastasis. Cancer Res. 2009;69(4):1279–83.CrossRefGoogle Scholar
  17. 17.
    Saver AL, Li LH, Subramanian S. MicroRNA miR-183 functions as an oncogene by targeting the transcription factor EGR1 and promoting tumor cell migration. Cancer Res. 2010;70(23):9570–80.CrossRefGoogle Scholar
  18. 18.
    Gu W, Gao T, Shen J, Sun Y, Zheng X, Wang J, et al. MicroRNA-183 inhibits apoptosis and promotes proliferation and invasion of gastric cancer cells by targeting PDCD4. Int J Clin Exp Med. 2014;7(9):2519–29.PubMedPubMedCentralGoogle Scholar
  19. 19.
    Ren LH, Chen WX, Li S, He XY, Zhang ZM, Li M, et al. MicroRNA-183 promotes proliferation and invasion in oesophageal squamous cell carcinoma by targeting programmed cell death 4. Br J Cancer. 2014;111(10):2003–13.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Qiu M, Liu L, Chen L, Tan G, Liang Z, Wang K, et al. microRNA-183 plays as oncogenes by increasing cell proliferation, migration and invasion via targeting protein phosphatase 2A in renal cancer cells. Biochem. Biophys. Res. Compt Rendus Geosci. 2014;452(1):163–9.Google Scholar
  21. 21.
    Wang GF, Mao WM, Zheng S. MicroRNA-183 regulates Ezrin expression in lung cancer cells. FEBS Lett. 2008;582(25-26):3663–8.CrossRefPubMedGoogle Scholar
  22. 22.
    Wellner U, Schubert J, Burk UC, Schmalhofer O, Zhu F, Sonntag A, et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol. 2009;11(2):1487–95.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2016

Authors and Affiliations

  • Conghui Zhu
    • 1
  • Xi Deng
    • 2
    • 3
  • Jingbo Wu
    • 2
  • Jianwen Zhang
    • 2
  • Hongru Yang
    • 2
  • Shaozhi Fu
    • 2
  • Yan Zhang
    • 4
  • Yunwei Han
    • 2
  • Yuanmei Zou
    • 2
  • Zhengtang Chen
    • 1
    Email author
  • Sheng Lin
    • 2
    Email author
  1. 1.Institute of Cancer, Xiqiao HospitalThird Military Medical UniversityChongqingChina
  2. 2.Department of OncologyThe Affiliated Hospital of Southwest Medical UniversityLuzhouChina
  3. 3.Ultrasonography, Xiqiao HospitalThird Military Medical UniversityChongqingChina
  4. 4.Nuclear Medicine DepartmentThe First Affiliated Hospital of Sichuan Medical UniversityLuzhouChina

Personalised recommendations